Novo Nordisk A/S (NVON)
Mexican Exchange · Mexico · prices in MXN · close of 23 Oct 2026
Key indicators
| Last close | MXN 726.00 |
|---|---|
| 52-week range | 637.43 – 1,119.03 |
| Return, 1 month / 3 months | +8.5% / −13.3% |
| Return, 1 year / 3 years | −22.2% / −57.0% |
| Trend | Below its 200-day average |
| RSI (14) | 53 |
| Volatility (1 year) | 45.9% |
| Worst drawdown (1 year) | -41.9% |
| Average daily value traded | 5.33M MXN |
| Dividend yield | 12.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Novo Nordisk is a pharmaceutical company based in Denmark that develops and makes medicines for people with diabetes and other chronic conditions. Its products include insulin preparations and other injectable diabetes treatments, along with therapies for growth disorders and bleeding disorders. It also supplies devices used to deliver these medicines. The company serves patients and healthcare professionals through sales in many countries, working with doctors, clinics and health systems that prescribe and distribute its treatments.
Novo Nordisk A/S trades under the code NVON on the Mexican Exchange in Mexico, with its price quoted in Mexican pesos (MXN). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Novo Nordisk A/S (NVON) trades on the Mexican Exchange in Mexico. It last closed at MXN 726.00 on 23 October 2026.
Its price-based Market X-Ray is 34 out of 100 (a weak price profile), ranking 297 of 361 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 22.2% and over the last three months it fell 13.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Mexican Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 20 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -5.3% | ||
| From 52-week high | -34.6% | ||
| Momentum | 27 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -13.3% | ||
| 6-month return | 9.9% | ||
| 12-month return, skipping the last month | -28.3% | ||
| Stability (higher is calmer) | 18 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 45.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -41.9% | ||
| Liquidity | 75 · Strong | Trades actively. | |
| Average daily value traded | 5.33M MXN | ||
| Zero-volume days | 0.0% | ||
| Income | 66 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 12.9% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +1.4% |
|---|---|
| 1 month | +8.5% |
| 3 months | −13.3% |
| 6 months | +9.9% |
| 1 year | −22.2% |
| 3 years | −57.0% |
| 5 years | −23.8% |
Signals
| 50-day / 200-day average | 735.70 / 766.84 |
|---|---|
| Golden / death cross (60 days) | Death, 20 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 15.16 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 17 Aug 2026 | DKK 10.7029 |
| 30 Mar 2026 | DKK 22.4959 |
| 18 Aug 2025 | DKK 10.7977 |
| 31 Mar 2025 | DKK 21.1134 |
| 16 Aug 2024 | DKK 9.5518 |
| 22 Mar 2024 | DKK 17.1732 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Mexican Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.